Kumar B, Kabekkodu S, Pai K
Mol Divers. 2025; .
PMID: 40009150
DOI: 10.1007/s11030-025-11132-7.
Estevam G, Linossi E, Rao J, Macdonald C, Ravikumar A, Chrispens K
Elife. 2025; 13.
PMID: 39960754
PMC: 11832172.
DOI: 10.7554/eLife.101882.
Bhuiyan M, Ahmed K, Reza M, Hossain H, Siam S, Nayan S
Heliyon. 2025; 11(2):e41749.
PMID: 39897831
PMC: 11786634.
DOI: 10.1016/j.heliyon.2025.e41749.
Mao W, Jiang J, Xia Y, Zhang L
Sci Rep. 2025; 15(1):3108.
PMID: 39856211
PMC: 11760955.
DOI: 10.1038/s41598-025-86959-z.
Abd Elhameed A, Ali A, Ghabbour H, Bayomi S, El-Gohary N
RSC Med Chem. 2025; .
PMID: 39850549
PMC: 11753467.
DOI: 10.1039/d4md00754a.
Mapping Protein Conformational Landscapes from Crystallographic Drug Fragment Screens.
Saeed A, Klureza M, Hekstra D
J Chem Inf Model. 2024; 64(23):8937-8951.
PMID: 39530154
PMC: 11633654.
DOI: 10.1021/acs.jcim.4c01380.
AXL and SHC1 confer crizotinib resistance in patient-derived xenograft model of ALK-driven lung cancer.
Hu Y, Zhou Y, Liu W, Chen M, Hao Y, Qu G
iScience. 2024; 27(9):110846.
PMID: 39310759
PMC: 11416680.
DOI: 10.1016/j.isci.2024.110846.
Mapping protein conformational landscapes from crystallographic drug fragment screens.
Saeed A, Klureza M, Hekstra D
bioRxiv. 2024; .
PMID: 39131376
PMC: 11312500.
DOI: 10.1101/2024.07.29.605395.
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.
Estevam G, Linossi E, Rao J, Macdonald C, Ravikumar A, Chrispens K
bioRxiv. 2024; .
PMID: 39071407
PMC: 11275805.
DOI: 10.1101/2024.07.16.603579.
Novel hematopoietic progenitor kinase 1 inhibitor KHK-6 enhances T-cell activation.
Ahn M, Kim E, Choi Y, Chae C, Kim P, Kim S
PLoS One. 2024; 19(6):e0305261.
PMID: 38923962
PMC: 11207149.
DOI: 10.1371/journal.pone.0305261.
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models.
Ren F, Aliper A, Chen J, Zhao H, Rao S, Kuppe C
Nat Biotechnol. 2024; 43(1):63-75.
PMID: 38459338
PMC: 11738990.
DOI: 10.1038/s41587-024-02143-0.
Back-pocket optimization of 2-aminopyrimidine-based macrocycles leads to potent dual EPHA2/GAK kinase inhibitors with antiviral activity.
Gerninghaus J, Zhubi R, Kramer A, Karim M, Nhu Tran D, Joerger A
bioRxiv. 2024; .
PMID: 38405908
PMC: 10888910.
DOI: 10.1101/2024.02.18.580805.
Potts Hamiltonian Models and Molecular Dynamics Free Energy Simulations for Predicting the Impact of Mutations on Protein Kinase Stability.
Thakur A, Gizzio J, Levy R
J Phys Chem B. 2024; 128(7):1656-1667.
PMID: 38350894
PMC: 10939730.
DOI: 10.1021/acs.jpcb.3c08097.
Discovery of dual kinase inhibitors targeting VEGFR2 and FAK: structure-based pharmacophore modeling, virtual screening, and molecular docking studies.
Fouad M, Osman A, Abdelhamid N, Rashad M, Nabawy A, El Kerdawy A
BMC Chem. 2024; 18(1):29.
PMID: 38347617
PMC: 10863211.
DOI: 10.1186/s13065-024-01130-5.
Discovery of dual rho-associated protein kinase 1 (ROCK1)/apoptosis signal-regulating kinase 1 (ASK1) inhibitors as a novel approach for non-alcoholic steatohepatitis (NASH) treatment.
Zaky Y, Rashad M, Zaater M, El Kerdawy A
BMC Chem. 2024; 18(1):2.
PMID: 38172941
PMC: 10765837.
DOI: 10.1186/s13065-023-01081-3.
An unconventional gatekeeper mutation sensitizes inositol hexakisphosphate kinases to an allosteric inhibitor.
Aguirre T, Dornan G, Hostachy S, Neuenschwander M, Seyffarth C, Haucke V
Elife. 2023; 12.
PMID: 37843983
PMC: 10578927.
DOI: 10.7554/eLife.88982.
How many kinases are druggable? A review of our current understanding.
Anderson B, Rosston P, Ong H, Hossain M, Davis-Gilbert Z, Drewry D
Biochem J. 2023; 480(16):1331-1363.
PMID: 37642371
PMC: 10586788.
DOI: 10.1042/BCJ20220217.
Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
Nair P, Piehler J, Tvorogov D, Ross D, Lopez A, Gotlib J
Blood Cancer Discov. 2023; 4(5):352-364.
PMID: 37498362
PMC: 10472187.
DOI: 10.1158/2643-3230.BCD-22-0189.
Synthesis and Development of Highly Selective Pyrrolo[2,3-]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Form.
Aarhus T, Bjornstad F, Wolowczyk C, Larsen K, Rognstad L, Leithaug T
J Med Chem. 2023; 66(10):6959-6980.
PMID: 37191268
PMC: 10226129.
DOI: 10.1021/acs.jmedchem.3c00428.
Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present).
Sandor A, Ionut I, Marc G, Oniga I, Eniu D, Oniga O
Pharmaceuticals (Basel). 2023; 16(4).
PMID: 37111291
PMC: 10141396.
DOI: 10.3390/ph16040534.
